| abstract |
This disclosure relates to inhibition of the Iroquois family of nucleic acids and/or proteins, such as IRX1, IRX2, IRX3, IRX4, IRX5, or IRX6 in the treatment of hyperproliferative disorders. In particular, pharmaceuticals and other compositions including an IRX5 inhibitor (such as an IRX5-specific siRNA or shRNA and methods of using IRX5 inhibitors (alone or in combination therapy)to treat hyperproliferative disorders (such as neoplasia) are described. |